New shot could tame rare bleeding disorder

NCT ID NCT07347249

Recruiting now Disease control Sponsor: Hemab ApS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 4 times

Summary

This study tests a new drug called sutacimig in 18 adults with a rare inherited bleeding disorder (factor VII deficiency). The drug is given as a single shot under the skin to see if it is safe and can help prevent bleeding. The goal is to find a more convenient treatment option for people who currently need frequent infusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sutacimig (a bispecific antibody given as a shot under the skin)
What this could lead to: If it works, this could point toward a new preventive treatment to reduce bleeding episodes in people with factor VII deficiency.
What could go wrong: This is a very early, small Phase 2 trial with only 18 people, so results may not apply to everyone. The drug is still experimental, and safety or effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates